HOME - AnGes,Inc.

2017.04.25	AnGes Announces FDA Clearance of Investigational New Drug (IND) Application for NF-kappaB decoy oligo DNA to treat discogenic lower back pain

2017.03.24	Investigational New Drug (IND) Application Submitted to the FDA Initiating a clinical trial with NF-kappaB decoy for the treatment of discogenic lower back pain

2017.02.20	Announcement Regarding Decrease in the Amount of Stated Capital and Capital Reserve and Appropriation of Surplus

2017.02.20	Notice Concerning Change of Trade Name

2016.10.03	Summary of Announcement Regarding Issue of Stock Acquisition Rights Completion of 28th Series of Stock Acquisition Rights (Private Placement) (with Option to Revise Exercise Price)

2016.08.05	Summary of Announcement Regarding Issue of Stock Acquisition Rights 28th Series of Stock Acquisition Rights(Private Placement) (with Option to Revise Exercise Price)

2016.08.01	AnGes Announces Investment in Vical

2017.03.02	Notice of Convocation Annual General Meeting 2017

2017.02.03	Consolidated Financial Report for 2016

2015.06.05	AnGes will attend the 2015 BIO International Convention on June 15th-18th in Philadelphia, PA

2015.06.05	AnGes’s gene medicine development featured in Nature Biopharma Dealmakers June 2015 Issue